China Healthcare Sector's Recovery Momentum May Continue in 2025 -- Market Talk

Dow Jones

2024-12-10

0250 GMT - The recovery momentum seen in China's healthcare companies since mid-August is expected to continue in 2025, says Cyrus Ng, an analyst at Deutsche Bank. The recovery should be helped by the Chinese government's supportive policy on innovative drugs and pricing, and an expected improvement in biotech funding, he says in a note. China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment, he notes. However, with improvement in sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025, he says. Ng's sector picks include Beigene, Hansoh and CSPC. (monica.gupta@wsj.com)

(END) Dow Jones Newswires

December 09, 2024 21:50 ET (02:50 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2490030334"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2490030334\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2490030334?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 10:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490030334","market":"hk","top_or_hot":-1,"title":"China Healthcare Sector's Recovery Momentum May Continue in 2025 -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0250 GMT - The recovery momentum seen in China's healthcare companies since mid-August is expected to continue in 2025, says Cyrus Ng, an analyst at Deutsche Bank. The recovery should be helped by the Chinese government's supportive policy on innovative drugs and pricing, and an expected improvement in biotech funding, he says in a note. China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment, he notes. However, with improvement in sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025, he says. Ng's sector picks include Beigene, Hansoh and CSPC. (monica.gupta@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 09, 2024 21:50 ET (02:50 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Healthcare Sector's Recovery Momentum May Continue in 2025 -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Healthcare Sector's Recovery Momentum May Continue in 2025 -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-10 10:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0250 GMT - The recovery momentum seen in China's healthcare companies since mid-August is expected to continue in 2025, says Cyrus Ng, an analyst at Deutsche Bank. The recovery should be helped by the Chinese government's supportive policy on innovative drugs and pricing, and an expected improvement in biotech funding, he says in a note. China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment, he notes. However, with improvement in sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025, he says. Ng's sector picks include Beigene, Hansoh and CSPC. (monica.gupta@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 09, 2024 21:50 ET (02:50 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1807302812.USD","symbol_name":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2490030334","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490030334","pubTimestamp":1733799000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0250 GMT - The recovery momentum seen in China's healthcare companies since mid-August is expected to continue in 2025, says Cyrus Ng, an analyst at Deutsche Bank. The recovery should be helped by the Chinese government's supportive policy on innovative drugs and pricing, and an expected improvement in biotech funding, he says in a note. China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment, he notes. However, with improvement in sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025, he says. Ng's sector picks include Beigene, Hansoh and CSPC. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","BK1521":"挪威政府全球养老基金持仓","BK1191":"制药","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","BK4505":"高瓴资本持仓","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","BK4504":"桥水持仓","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","BK4548":"巴美列捷福持仓","HCSG":"医疗保健服务","IE0008368742.USD":"首域中国增长基金I Acc","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","BK4137":"综合支持服务","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","BK1589":"北水核心资产","BK1515":"抗疫概念","BK4585":"ETF&股票定投概念","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","BK4139":"生物科技","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","BK1583":"高瓴概念","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","BK4535":"淡马锡持仓","03692":"翰森制药","BK4526":"热门中概股","BK4588":"碎股","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","01093":"石药集团"},"translate_title":"2025年中国医疗保健行业复苏势头或将持续——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":0.9,"03692":0.9,"BGNE":0.9,"HCSG":1},"content_text":"0250 GMT - The recovery momentum seen in China's healthcare companies since mid-August is expected to continue in 2025, says Cyrus Ng, an analyst at Deutsche Bank. The recovery should be helped by the Chinese government's supportive policy on innovative drugs and pricing, and an expected improvement in biotech funding, he says in a note. China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment, he notes. However, with improvement in sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025, he says. Ng's sector picks include Beigene, Hansoh and CSPC. (monica.gupta@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2024 21:50 ET (02:50 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}